JENA, Germany—Carl Zeiss Meditec (ISIN: DE 0005313704) generated revenue of €410.2 million in the first three months of fiscal year 2021/22, versus prior year of €368.9 million, corresponding to an increase of 11.2 percent adjusted for currency effects of +10.5 percent compared with the same period of the prior year. Orders received increased at a much higher rate than revenue, rising 24.0 percent to €498.3 million versus prior year of €401.7 million, according to an announcement last week from the company.

Earnings before interest and tax (EBIT) increased slightly to €74.4 million versus prior year of €73.4 million, including one-time extraordinary income of €2.4 million. The EBIT margin was 18.1 percent (prior year: 19.9 percent). The adjusted EBIT margin was 18.6 percent (prior year: 19.8 percent).

Dr. Markus Weber, president and CEO of Carl Zeiss Meditec AG since Jan. 1, 2022, said, “As in fiscal year 2020/21, we are still dealing with a challenging environment: the pandemic is not yet entirely behind us—the global supply chains, especially, remain very strained. I am therefore all the more delighted with the continued strong demand for our solutions—orders received were at a record high at the start of the year.”

Revenue in the Ophthalmic Devices strategic business unit (SBU) increased by 9.7 percent in the first three months of fiscal year 2021/22 (adjusted for currency effects: +9.1 percent), to €310.9 million (prior year: €283.4 million). Recurring revenue from consumables, implants and services once again made significant contributions to growth.

Orders received in the Ophthalmic Devices SBU increased disproportionately to revenue. Revenue in the Microsurgery SBU increased by 16.1 percent (adjusted for currency effects: +15.2 percent) to €99.3 million (prior year: €85.5 million). Orders received in the Microsurgery SBU likewise increased at a much higher rate than revenue.

Revenue in the EMEA region increased by 5.0 percent (adjusted for currency effects: +5.9 percent) to €114.1 million (prior year: €108.7 million). Orders received in the core European markets exhibited a positive trend.

The Americas region recorded a revenue increase of 12.3 percent (adjusted for currency effects: +8.4 percent) to €114.5 million (prior year: €102.0 million). The U.S. and the countries of South America both contributed to this.

In the APAC region, revenue increased to €181.5 million, compared with €158.2 million in the prior year (+14.8 percent; adjusted for currency effects: +15.1 percent). The strongest contributions to growth came from China and India. Japan recorded a strong order intake.

The company’s outlook for fiscal year 2021/22 remains unchanged: revenue is expected to grow at least to the same extent as the market. One uncertainty is posed by the continued strain in the global supply chains. The new products launched at the end of the fiscal year under review in the Ophthalmic Devices SBU, which included the Visumax 800 and the Quatera 700, were met with a good level of interest.

Initial orders and installations were made in the first quarter of fiscal year 2021/22. Due, among other things, to still pending approval processes, however, the management board does not expect these new products to make any significant contribution to revenue in the current fiscal year, the company said.